Slide 1: Exchange cover letter: Presentation – Q4 FY26 Earnings Call
Biocon Limited 20th KM, Hosur Road Electronic City Bangalore 560 100, India T 91 80 2808 2808 F 91 80 2852 3423 CIN : L24234KA1978PLC003417 www.biocon.com BIO/SECL/TG/2026-27/16 May 08, 2026 To, To, The Secretary The Secretary BSE Limited National Stock Exchange of India Limited Department of Corpor
Slide 2: Biocon Limited Q4 and Full Year FY26 Earnings Call
Biocon Limited Q4 and Full Year FY26 Earnings Call 08 – May – 2 0 2 6
Slide 3: Safe Harbor Statement
Safe Harbor Statement Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking s
Slide 4: Chairperson's Opening Remarks
Chairperson’s Opening Remarks
Slide 5: Q4 & Full Year FY26 Performance Overview
Q4 & Full Year FY26 Performance Overview FY26: A Clear Inflection Point o Strong close to an important year despite a challenging external environment o Transition completed from integration and investment-phase to execution and value creation One Unified Global Biopharma Platform o Integration of B
Slide 6: Financial Highlights Q4 & Full Year FY26
Financial Highlights Q4 & Full Year FY26
Slide 7: Financial Highlights – Q4 FY26
Financial Highlights – Q4 FY26 Q4 FY25 (Ex- In ₹ Cr Q4 FY26 Q4 FY25 Q3 FY26 YoY% (Adj)* QoQ% Lenalidomide) Generics 847 1,048 748 851 13 (1) Biosimilars 2,756 2,463 2,463 2,497 12 10 CRDMO 1,037 1,018 1,018 917 2 13 Revenue from Operations 4,517 4,417 4,117 4,173 10 8 Total Revenue 4,569 4,454 4,154
Slide 8: Financial Highlights – FY26
Financial Highlights – FY26 FY25 (Ex-Lena., BFI In ₹ Cr FY26 FY25 YoY% (Adj)* divestment gain) Generics 3,168 3,017 2,717 17 Biosimilars 10,431 9,017 9,017 16 CRDMO 3,739 3,642 3,642 3 Revenue from Operations 16,927 15,262 14,962 13 Total Revenue 17,270 16,470 15,113 14 R&D (Net) 982 859 859 14 % of
Slide 9: Biosimilars
Biosimilars
Slide 10: Biosimilars: Q4 & FY26 Business Performance update
Biosimilars: Q4 & FY26 Business Performance update FY26: Continued Focus on Execution Q4 Q4 Q3 In ₹ Cr YoY% QoQ% FY26 FY25 FY26 o Portfolio expanded with multiple approvals and launches now in place Segment o Business transitioning from investment phase to scale-up and 2,756 2,463 2,497 12 10 Revenu
Slide 11: Generics
Generics
Slide 12: Generics: Q4 & FY26 Business Performance update
Generics: Q4 & FY26 Business Performance update Q4 FY25 FY26: Portfolio Expansion Q4 Q4 Q3 YoY% QoQ In ₹ Cr (Ex- o Multiple approvals secured across markets FY26 FY25 FY26 (Adj)* % Lena.) o gLiraglutide approvals across the US, EU and Australia expanded Segment 847 1,048 748 851 13 (1) the GLP-1 fra
Slide 13: CRDMO
CRDMO
Slide 14: CRDMO: Q4 & FY26 Business Performance update
CRDMO: Q4 & FY26 Business Performance update Business Performance o FY26 revenue up 3% YoY, Q4 revenue up 2% YoY Q4 Q4 Q3 QoQ In ₹ Cr YoY% Business Resilience and Client Momentum FY26 FY25 FY26 % o Strong execution and compliance demonstrated through multiple Segment 1,037 1,018 917 2 13 audits comp
Slide 15: Concluding Remarks
Concluding Remarks
Slide 16: Concluding Remarks: Q4 & Full Year FY26
Concluding Remarks: Q4 & Full Year FY26 FY26: Corporate Reorganization Completed o Integration complete; major investment phase behind us o One unified global biopharma platform with a stronger balance sheet FY27: Focused on Execution and Improvement o Scaling of recent biosimilars launches to drive
Slide 17: Biocon – Q&A
$ Biocon REACH EXPANDING ACCESS PROPELLING GROWTH Q&A